<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: To determine prospectively the efficacy, tolerability and patient satisfaction of an extended release formulation of <z:chebi fb="0" ids="6801">metformin</z:chebi> (<z:chebi fb="0" ids="6801">metformin</z:chebi> XR) in hospital based outpatients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> currently treated with standard <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Patients on immediate release standard <z:chebi fb="0" ids="6801">metformin</z:chebi> either alone or combined with other oral agents were switched to extended release <z:chebi fb="0" ids="6801">metformin</z:chebi> XR 500 mg tablets and titrated to a maximum dose of 2000 mg/day Measurements to include <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipid</z:chebi> control, blood pressure, body weight, waist circumference, C-reactive protein, adverse events and patient satisfaction were recorded at baseline, three and six months </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Complete data were obtained for 35 of the 61 patients enrolled to the study </plain></SENT>
<SENT sid="3" pm="."><plain>At three and six months no changes were reported for any of the <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> except for <z:chebi fb="23" ids="18059">lipids</z:chebi> where there was a modest rise in plasma <z:chebi fb="4" ids="17855">triglycerides</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>These effects were achieved with a reduced dose of <z:chebi fb="0" ids="6801">metformin</z:chebi> XR compared to pre-study dosing with standard <z:chebi fb="0" ids="6801">metformin</z:chebi> (1500 mg +/- 402 vs 1861 +/- 711 p = 0.004) </plain></SENT>
<SENT sid="5" pm="."><plain>A total of 77% of patients were free of gastrointestinal side effects and 83% of patients stated a preference for <z:chebi fb="0" ids="6801">metformin</z:chebi> XR at the end of the study </plain></SENT>
<SENT sid="6" pm="."><plain>Ghost tablets were reported in the faeces by the majority of the patients (54.1%) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Patients switched to extended release <z:chebi fb="0" ids="6801">metformin</z:chebi> XR derived the same clinical and metabolic benefits as for standard <z:chebi fb="0" ids="6801">metformin</z:chebi> but with reduced dosage, fewer gastrointestinal side effects and a greater sense of well being and satisfaction on medication </plain></SENT>
</text></document>